Phospho-MAP3K7 (T184) Antibody

What is MAP3K7/TAK1 and what is the significance of its phosphorylation at T184?

MAP3K7, also known as TAK1 (Transforming growth factor-beta-activated kinase 1), is a member of the serine/threonine protein kinase family that plays crucial roles in multiple signaling pathways. This kinase mediates signal transduction induced by TGF-beta and bone morphogenetic protein (BMP), controlling various cell functions including transcription regulation and apoptosis . Phosphorylation at threonine 184 (T184) represents a critical activation mechanism for TAK1. When phosphorylated at this residue, TAK1 becomes enzymatically active and can transmit signals to downstream effectors, particularly in inflammatory and immune response pathways. In response to IL-1 stimulation, TAK1 forms a kinase complex with TRAF6, TAB1 (MAP3K7P1), and TAB2 (MAP3K7P2), which is essential for the activation of nuclear factor kappa B (NF-κB) .

How does the Phospho-MAP3K7 (T184) Antibody function in research applications?

The Phospho-MAP3K7 (T184) Antibody is specifically designed to detect endogenous levels of the TAK1 protein only when phosphorylated at threonine 184 . This highly specific recognition capability makes it an invaluable tool for studying TAK1 activation status in various experimental conditions. The antibody was developed using synthesized peptides derived from human TAK1 surrounding the phosphorylation site of T184 (typically within the region of amino acids 130-210) . To ensure specificity, the antibody is affinity-purified from rabbit antiserum through affinity-chromatography using the epitope-specific immunogen . This purification process enhances the antibody's sensitivity and reduces background signals in experimental applications.

What are the standard applications for Phospho-MAP3K7 (T184) Antibody?

Phospho-MAP3K7 (T184) Antibody has been validated for multiple experimental applications:

• Western Blot (WB): Recommended dilution range of 1:500-1:2000, allowing for detection of phosphorylated TAK1 protein in cell or tissue lysates

• Immunohistochemistry (IHC): Effective at dilutions of 1:100-1:300 for both paraffin-embedded (IHC-P) and frozen sections (IHC-F)

• Enzyme-Linked Immunosorbent Assay (ELISA): Highly sensitive at dilutions up to 1:10000, particularly useful for quantitative detection

• Immunofluorescence (IF): Applicable for both IHC-P and IHC-F formats, as well as immunocytochemistry (ICC)

The antibody's versatility across multiple techniques makes it particularly valuable for research requiring confirmation of findings through complementary methodologies.

What are the optimal storage and handling conditions for Phospho-MAP3K7 (T184) Antibody?

For maximum stability and performance of Phospho-MAP3K7 (T184) Antibody, researchers should adhere to the following storage and handling guidelines:

• Store the antibody at -20°C for long-term preservation

• Avoid repeated freeze/thaw cycles that can compromise antibody integrity and performance

• The antibody is typically supplied in liquid format at a concentration of 1 mg/mL in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Some formulations may include TBS (pH 7.4) with 1% BSA, 0.02% Proclin300, and 50% Glycerol

• When working with the antibody, aliquot into smaller volumes upon receipt to minimize freeze/thaw cycles

• Allow the antibody to equilibrate to room temperature before opening the vial to prevent condensation that might dilute or contaminate the reagent

What species reactivity can be expected with Phospho-MAP3K7 (T184) Antibody?

The Phospho-MAP3K7 (T184) Antibody has been validated to react with samples from multiple species:

How can Cell-Based ELISA using Phospho-MAP3K7 (T184) Antibody enhance phosphorylation studies?

Cell-Based ELISA represents an advanced approach to studying MAP3K7 phosphorylation that offers several advantages over traditional Western blot analysis:

The Cell-Based Phospho-MAP3K7 (T184) ELISA Kit enables detection of MAP3K7 phosphorylation at T184 directly in cultured cells . This technique allows for:

• Higher throughput analysis: Performed in 96-well microplates, allowing multiple conditions to be tested simultaneously

• Quantitative measurement: Provides more accurate quantification of relative phosphorylation levels compared to semi-quantitative Western blot analysis

• Conservation of materials: Requires fewer cells and reagents than traditional protein analysis methods

• Normalization options: Multiple normalization methods are available:

  • Using anti-GAPDH antibody as an internal positive control

  • Crystal violet whole-cell staining to adjust for cell density differences

  • Parallel detection of total MAP3K7 to normalize phosphorylation levels

• Time efficiency: Results can be obtained more rapidly and are readily available for analysis using standard ELISA plate readers

This approach is particularly valuable for screening studies, dose-response analyses, and time-course experiments examining TAK1 activation under various conditions.

What is the significance of dual phosphorylation at T184 and T187 sites of MAP3K7?

TAK1 activation involves phosphorylation at multiple sites, with T184 and T187 being particularly important regulatory sites. The dual phosphorylation at these residues represents a complex regulatory mechanism:

• Phosphorylation at T184 is often the initial event in TAK1 activation

• Some antibodies specifically detect dual phosphorylation at both T184 and T187 sites , indicating that these events may occur sequentially or simultaneously depending on the stimulus

• The dual phosphorylation state is associated with full enzymatic activation of TAK1

• Different stimuli may induce distinct phosphorylation patterns, potentially leading to varying downstream effects

Understanding the precise dynamics between these phosphorylation events requires careful experimental design using site-specific antibodies. Researchers studying TAK1 activation mechanisms should consider using both single-site (T184) and dual-site (T184+T187) phospho-specific antibodies to fully characterize activation patterns in their experimental systems.

How does MAP3K7/TAK1 phosphorylation at T184 relate to specific signaling pathways?

MAP3K7/TAK1 phosphorylation at T184 serves as a critical regulatory node in multiple signaling cascades:

• TGF-β/BMP Signaling: Phosphorylated TAK1 mediates non-canonical TGF-β signaling, leading to activation of p38 MAPK and JNK pathways rather than the canonical SMAD pathway

• Inflammatory Signaling: In response to IL-1 and TNF-α, TAK1 phosphorylation at T184 is essential for:

  • Activation of the IKK complex, leading to NF-κB-dependent transcription

  • Initiation of MAPK cascades through phosphorylation of MAP2K3/MKK3, MAP2K6/MKK6, and MAP2K7/MKK7

• Toll-like Receptor (TLR) Signaling: Phospho-TAK1 mediates innate immune responses downstream of TLRs

• CD40 and B-cell Receptor Signaling: TAK1 phosphorylation contributes to adaptive immune responses

• Ceramide-Induced Signaling: Beyond protein-protein interactions, ceramides can also activate TAK1 through phosphorylation

When designing experiments to study these pathways, researchers should consider the appropriate stimuli (cytokines, growth factors, receptor agonists) and time points for capturing T184 phosphorylation events. Phosphatase inhibitors should be included in lysis buffers to preserve phosphorylation status during sample preparation.

What controls should be included when using Phospho-MAP3K7 (T184) Antibody?

Proper experimental controls are essential for reliable interpretation of results when working with phospho-specific antibodies:

• Positive Controls:

  • Cell lines known to exhibit TAK1 phosphorylation (e.g., cells treated with IL-1β, TNF-α, or TGF-β)

  • Recombinant phosphorylated TAK1 protein (if available)

  • GAPDH detection as an internal loading control for normalization

• Negative Controls:

  • Untreated cells with low basal phosphorylation

  • Phosphatase-treated samples to demonstrate phospho-specificity

  • Cells treated with specific TAK1 inhibitors

• Specificity Controls:

  • Parallel detection of total TAK1 protein to normalize phosphorylation levels

  • Peptide competition assays using the phosphopeptide immunogen

  • Secondary antibody-only controls to assess non-specific binding

• Normalization Controls:

  • For Cell-Based ELISA, crystal violet staining for cell number normalization

  • Total protein staining (e.g., Ponceau S) for Western blot loading control

Implementing these controls will substantially enhance the reliability and interpretability of experimental results involving Phospho-MAP3K7 (T184) Antibody.

How can I optimize Western blot protocols for Phospho-MAP3K7 (T184) detection?

Detecting phosphorylated proteins by Western blot requires careful optimization:

• Sample Preparation:

  • Use phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) in lysis buffers

  • Process samples quickly and keep them cold to minimize dephosphorylation

  • Use appropriate stimuli and time points to maximize phosphorylation signal

• Gel Electrophoresis and Transfer:

  • Consider using Phos-tag™ acrylamide gels for enhanced separation of phosphorylated vs. non-phosphorylated forms

  • Ensure complete transfer of higher molecular weight proteins by optimizing transfer conditions

• Antibody Incubation:

  • Start with the recommended dilution range (1:500-1:2000) and optimize as needed

  • Consider longer primary antibody incubation (overnight at 4°C) to enhance sensitivity

  • Use 5% BSA rather than milk for blocking and antibody dilution, as milk contains phosphoproteins that may increase background

• Signal Development:

  • Enhanced chemiluminescence (ECL) or fluorescent secondary antibodies can be used depending on required sensitivity

  • For weakly phosphorylated targets, consider using signal amplification systems

• Stripping and Reprobing:

  • For comparison with total TAK1, mild stripping conditions should be used to avoid removing all proteins from the membrane

  • Consider running duplicate gels rather than stripping when possible

Following these optimization strategies will help ensure robust and reproducible detection of phosphorylated TAK1 in Western blot applications.

What approaches can differentiate between specific MAP3K7 phosphorylation states?

Distinguishing between different phosphorylation states of MAP3K7/TAK1 requires specialized approaches:

• Site-Specific Phospho-Antibodies:

  • Use antibodies targeting single phosphorylation sites (T184) vs. dual phosphorylation sites (T184+T187)

  • Compare results with total TAK1 antibodies to determine the proportion of phosphorylated protein

• Phosphatase Treatment:

  • Treating duplicate samples with lambda phosphatase can confirm signal specificity

  • Different phosphatases have varying specificities and can help distinguish phosphorylation types

• Mass Spectrometry:

  • For definitive identification of phosphorylation sites, immunoprecipitate TAK1 and analyze by LC-MS/MS

  • This approach can identify all phosphorylation sites simultaneously

• Phosphomimetic Mutants:

  • Generate T184A (phospho-null) and T184E/D (phosphomimetic) mutants for functional studies

  • Compare with T187 mutants to distinguish roles of different phosphorylation sites

• Kinase Inhibitors:

  • Use specific upstream kinase inhibitors to block phosphorylation at particular sites

  • Time-course studies with inhibitors can reveal sequential phosphorylation events

These approaches, often used in combination, can provide comprehensive information about the complex phosphorylation patterns of TAK1 and their functional significance in various signaling contexts.

What are the current limitations in Phospho-MAP3K7 (T184) Antibody research?

Despite its utility, research using Phospho-MAP3K7 (T184) Antibody faces several challenges:

• Temporal dynamics: Capturing the often transient phosphorylation events requires careful timing of experiments

• Context-dependency: The phosphorylation patterns may vary significantly between cell types and stimuli

• Multi-site phosphorylation: The interplay between T184 and other phosphorylation sites (e.g., T187, S439) adds complexity to interpretation

• Antibody specificity: Cross-reactivity with other phosphorylated epitopes must be rigorously controlled

• Technical variability: Phosphoprotein detection is sensitive to sample preparation methods

Researchers should address these limitations through careful experimental design, appropriate controls, and validation using complementary techniques.

What emerging technologies might enhance phospho-MAP3K7 research?

Several advanced technologies show promise for enhancing research on MAP3K7 phosphorylation:

• Proximity ligation assays: For visualizing phosphorylation events in situ with enhanced sensitivity

• Phosphoproteomics: For comprehensive analysis of MAP3K7 phosphorylation and its downstream targets

• CRISPR-based phosphorylation reporters: For real-time monitoring of TAK1 phosphorylation in living cells

• Single-cell analysis techniques: To examine cell-to-cell variability in phosphorylation responses

• Cryo-EM and structural studies: To understand how phosphorylation at T184 affects TAK1 conformation and activity

These emerging approaches may provide deeper insights into the complex regulation of MAP3K7/TAK1 signaling pathways and their roles in normal physiology and disease.